Cannabis & Hemp Stocks Investment Tools – Schedule Demo Now!


Revive Therapeutics Moves Closer to a Possible COVID-19 Treatment

Revive Therapeutics Moves Closer to a Possible COVID-19 TreatmentOn Friday, Revive Therapeutics (OTC: RVVTF) announced that the U.S. Food & Drug Administration has approved the company to conduct a randomized, double-blind, placebo-controlled, Phase-3 clinical trial protocol in order to evaluate the effectiveness of Bucillamine as a treatment for patients with mild to moderate COVID-19. Consequently, the cannabis stock surged over 60% on the news. But will this cannabis stock continue to soar?

The Phase-3 study would enroll nearly 1,000 patients. The patients will be randomized 1:1:1 to be administered Bucillamine 100 mg 3x/ day, Bucillamine 200 mg 3x/ day, or placebo thrice a day for a period of 14 days.

Additionally, Revive indicates that it intends to follow up with the submission of the complete CTA package for Health Canada around its Phase 3 study as part of the same clinical strategy.

Revive’s Strong IP Portfolio

Revive Therapeutics Moves Closer to a Possible COVID-19 Treatment

Revive Therapeutics’ Intellectual Property comprises cannabis, psilocybin, and bucillamine. The prospective treatment for COVID-19 that has proceeded up to the Phase-3 of the clinical trial highlights the power of Bucillamine that forms the core of the cannabis stock’s IP.

On the cannabis front, Revive focusses on the treatment of rare inflammatory diseases through its cannabinoid pharmaceutical portfolio. The cannabis pharma company was granted FDA orphan drug status designation for using CBD to treat autoimmune hepatitis (liver disease), as well as to treat ischemia and reperfusion injury as a result of organ transplantation.

Revive’s psilocybin-based pharmaceuticals have also been in the news for quite some time. On 21 April, Revive announced a sponsored research partnership with the University of Wisconsin-Madison to evaluate unique formulations and drug delivery technology surrounding psilocybin.

Will Phase-3 trials Send the Cannabis Stock Higher?

Revive Therapeutics Moves Closer to a Possible COVID-19 Treatment

There are only a few companies that have reached Phase 2 and 3 trials for COVID-19 treatment and Revive may be the only cannabis pharmaceutical stock to tout such a milestone. In this light, we believe that entering into Phase-3 is a major achievement for Revive Therapeutics. If the results are successful, it is likely to give a significant boost to the cannabis stock’s revenue.

In the last few months, the other coronavirus vaccine stocks have also garnered maximum attention. With over 600,000 deaths globally and a rising number of cases, treatment for COVID-19 is desperately The curve has to be flattened.

Because of this, we believe that even Revive would gather plenty of interest from investors. On a YTD-basis, the cannabis stock has already surged nearly 50%. The latest news of the Phase-3 clinical trial is likely to push the stock higher. We recommend keeping an eye on this cannabis stock for 2020.

Algorithmic Stock Trading Identifies Profitable Revive Cannabis Stock Trade One Week in Advance

Revive Cannabis Stock Algorithmic Stocks Trades

Revive surged 60% on Friday. Cannin Members were instructed to buy this stock a week prior. Doug H. in Denver ended up making $759.00 from the trade. What are you waiting for? Sign up for your free month now and use algorithmic stock trading to identify profitable cannabis stock trades in advance.

Revive Therapeutics Moves Closer to a Possible COVID-19 Treatment


About Cannin: Your Cannabis Stocks Resource

About Cannin: Your Cannabis Stocks ResourceCannin is your #1 resource for cannabis stocks. Our global team of experts evaluates all emerging cannabis stock investing opportunities. We aggregate hundreds of hours of research and provide tips on the best cannabis stocks for 2020. 

Use Cannin as your resource for:

Is it too late to invest in cannabis stocks? No! This is the perfect time to invest.

Market analysts expect the cannabis industry will have an annual value exceeding $75 Billion in the next decade. The time to invest in cannabis stocks is now. Are you looking to buy stock in cannabis companies or hemp companies? Interested in emerging penny cannabis pharmaceutical stock companies? Looking for the best Canadian cannabis stocks to invest in? We can help.

Predict price movements of cannabis stocks several hours in advance with our proprietary algorithmic stock trading software.

  • +25% Gains in 2020
  • +49.8% Gains in 2019
  • Backtested since 2012

We’re so confident you’ll love our signals, we’re willing to give you a one-month risk-free trial to see it for yourself.

Profit from the best cannabis stocks – we’ll show you how at cannin.com